arrow
返回

Bronchiectasis: still a problem

delete2014-01-05
delete5
delete
OA
AI
Z
Zengli Wang *
DOI:10.3760/cma.j.issn.0366-6999.20132165delete
delete原文链接
delete分享
delete收藏
查看原文
摘要

摘要

En 中文
Objective The purpose of this descriptive review was to delineate the current knowledge of bronchiectasis in terms of prevalence, burden of disease, pathophysiology, and management. Data sources The National Library of Medicines MEDLINE and PubMed database (2005-2013) were used to conduct a search using the keyword term bronchiectasis. The references for articles being considered for inclusion were searched from additional sources such as conference proceedings. Study selection Criteria for inclusion of articles included data outlining epidemiology, pathogenesis, diagnosis, and evidence-based guidelines for management of bronchiectasis. In assessing the quality of the articles, factors such as size of the population studied, clinical setting of the study, and whether or not the studies were prospective or retrospective were taken into consideration. Review articles were also included in our data collection. Results Despite many advances in modern medicine, bronchiectasis still remains a significant public health problem in developed countries and the developing world. It carries a significant burden worldwide in terms of morbidity and mortality, as well as financially to the affected population. In addition, bronchiectasis may associate with chronic airflow obstruction, regardless of smoking status. Conclusions Bronchiectasis is a debilitating illness responsible for significant morbidity with a poor health-related quality of life. The condition has a substantial socioeconomic cost because both primary and secondary healthcare resources are frequently used and periods of sick leave are common.
Keyword:
bronchiectasis
prevalence
burden
management
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Chinese Medical Journal 封面图
Chinese Medical Journal
IF:
7.3
论文数:
1.2W
被引数:
1.5W

机构

暂无机构信息
引用论文

引用论文

Large Shareholder Diversification and Corporate Risk-Taking
err2011-01-01
err0
errOAAI
errMara Faccio; Roberto Mura; Maria-Teresa Marchica
err分享
err收藏
Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis
err2012-09-27
err26
PREAI
errMandal, P.; Sidhu, M. K.; Donaldson, L. S.; Chalmers, J. D.; Smith, M. P.; Turnbull, K.; Scott, J.; Hill, A. T.
err分享
err收藏
err分享
err收藏
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
errTHORAX
IF7.7
err2013-05-16
err208
errOAAI
errSerisier, David J.; Bilton, Diana; De Soyza, Anthony; Thompson, Philip J.; Kolbe, John; Greville, Hugh W.; Cipolla, David; Bruinenberg, Paul; Gonda, Igor
err分享
err收藏
Optimal trade credit and replenishment policies for non-instantaneous deteriorating items
err2020-09-16
err0
errOAAI
errAnuj Kumar Sharma; Sunil Tiwari; V.S.S. Yadavalli; Chandra K. Jaggi
err分享
err收藏
Phase 3 Randomized Study of the Efficacy and Safety of Inhaled Dry Powder Mannitol for the Symptomatic Treatment of Non-Cystic Fibrosis Bronchiectasis吸入干粉甘露醇对症治疗非囊性纤维化支气管扩张的疗效和安全性的3期随机研究
errCHEST
IF8.6
err2013-07-01
err91
PREAI
errBilton, Diana; Daviskas, Evangelia; Anderson, Sandra D.; Kolbe, John; King, Gregory; Stirling, Rob G.; Thompson, Bruce R.; Milne, David; Charlton, Brett
err分享
err收藏
学者 查看更多内容